- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04742257
Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity (RECOVER)
Multi-Center, Randomized, Sham-Controlled Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Stroke is the fifth leading cause of death in the U.S. and a leading cause of serious long-term disability. There are over 7.5 million patients in the U.S. living with stroke, and an estimated 795,000 additional cases of stroke occur annually in the U.S. Of these cases, approximately 610,000 represent initial attacks and 185,000 represent recurrent stroke according to the CDC.
Spasticity is a common finding in patients with stroke, arising in about 30% of stroke patients, and occurring usually within the first few days or weeks. It is a disorder of motor function that results from injury to the spinal cord or brain, and causes decreased motor performance as well as pain, discomfort and muscle weakness that greatly interferes with functional recovery. Spasticity can range from mild to severe and can cause striking impairments in functional movement.
An initial clinical trial of safety and feasibility suggests that five sessions of treatment with the MyoRegulator® device temporarily reduces spasticity and overall stiffness of the affected extremity with optimal reductions in spasticity occurring 2-3 weeks post stimulation intervention.
MyoRegulator® is a non-significant risk (NSR) investigational non-invasive neuromodulation device using multi-site direct current stimulation (multi-site DCS) for the treatment of spasticity. Multi-site DCS utilizes trans-spinal direct current stimulation (tsDCS) paired with transcutaneous peripheral direct current stimulation (pDCS). This study was designed to evaluate the efficacy and safety of MyoRegulator® in the treatment of post-stroke upper-limb spasticity.
The primary performance endpoint is defined as the reduction in wrist joint spasticity as measured using the Modified Ashworth Scale and will use a responder analysis. The study will be considered to have a successful outcome if a significant number of actively treated subjects respond to MyoRegulator® treatment as compared to the sham treated subjects following 5 days of treatment.
The primary safety endpoint is defined as the incidence of device-related serious adverse events. The safety of the device will be demonstrated if there are no incidents of serious adverse events caused or contributed to by the device treatment that are clinically unacceptable in light of the treatment benefits.
In order to evaluate the relationship between response to treatment and BDNF genotype, subjects will be asked to provide a saliva sample and give consent for BDNF genotyping.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sheila Hemeon-Heyer, J.D.
- Phone Number: 413-330-8578
- Email: sheyer@pmneuro.com
Study Locations
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02138
- Recruiting
- Spaulding Rehabilitation Hospital
-
Contact:
- Andrea Christoforou, P.T., Ph.D., M.Sc., N.C.S.
- Phone Number: 617-952-6818
- Email: achristoforou@partners.org
-
Charlestown, Massachusetts, United States, 02114
- Recruiting
- Spaulding Rehabilitation Hospital
-
Contact:
- Leon Morales-Quezada, M.D., Ph.D.
- Phone Number: 617-952-6162
- Email: jmorales-quezada@partners.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥ 18 to < 85 years of age
- First single focal unilateral hemisphere lesion with diagnosis verified by brain imaging (MRI or CT scans) that occurred at least 6 months prior to study enrollment
- At least 6 weeks of stable UE spasticity symptoms (as confirmed by medical history) with a baseline Modified Ashworth Scale (MAS) score of 1+ to 3 (on the 0, 1, 1+, 2, 3, 4 scale), inclusive, in the wrist flexor muscles
- Willing to forgo botulinum toxin, phenol or alcohol injections into the muscles of the limb targeted for the study treatment; intrathecal baclofen; digitalis, and morphine for the subject's duration in the study
- Willing to forgo upper extremity physical and occupational therapy for the duration of the study (lower extremity PT and OT are allowed)
- Willing to maintain current regiment for oral spasticity medication(s) and neurotransmitter medication(s) for the subject's duration in the study
- Cognitive function sufficient to understand the experiments and follow instructions (per interview with appropriate clinician)
Exclusion Criteria:
- Fixed contractures or profound muscle atrophy of the target spastic wrist to be treated
- Change in antispastic oral medication (baclofen, clonidine, benzodiazepine, dantrolene, gabapentin, tizanidine) in the 2 months prior to study enrollment
- Use of digitalis, morphine, or intrathecal pump in the week prior to study enrollment
- Prior botulinum toxin injection(s) into the muscles of the limb targeted for the study treatment within 12 weeks of study enrollment
- Prior phenol or alcohol injections into the muscles of the limb targeted for the study treatment within 6 months of study enrollment
- Prior surgery for spasticity in the target muscle group
- Prior transcranial or trans-spinal direct current stimulation for any reason
Presence of potential tsDCS risk factors:
- Damaged skin at the stimulation sites (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.)
- Lack of sensory perception at the stimulation sites
- Presence of an electrically, magnetically, or mechanically activated implant (including cardiac pacemaker) or any other electrically sensitive support system with the exception of loop recorders
- Ferrous metal in the path of the current flow (jewelry must be removed during stimulation)
- Past history of epileptic seizures or unexplained spells of loss of consciousness during the previous 36 months
- Other neurological conditions involving CNS impairment, including Parkinson's Disease, Multiple Sclerosis, and Spinal Cord Injury
- Any medical condition that would prevent the subject from being able to participate in the clinical outcome measures
- Previous participating in a study involving the application of tsDCS
- Pregnancy in women (as determined by pregnancy test in pre-menopausal women)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Stimulation
Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
|
Trans-spinal DCS paired with peripheral DCS
Other Names:
|
Sham Comparator: Sham Stimulation
Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
|
Trans-spinal DCS paired with peripheral DCS
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in wrist flexor spasticity following 5 days of treatment compared to baseline as measured by the Modified Ashworth Scale score
Time Frame: Up to 8 weeks post-treatment
|
The Modified Ashworth Scale is a validated clinical measurement for the evaluation of spasticity after stroke.
|
Up to 8 weeks post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Modified Ashworth Scale total upper limb score following 5 days of treatment as compared to baseline
Time Frame: Up to 8 weeks post-treatment
|
Here the Modified Ashworth Scale will be used to assess changes in spasticity in the entire upper limb.
|
Up to 8 weeks post-treatment
|
Change in Upper-Extremity Fugl-Meyer motor domain score following 5 days of treatment as compared to baseline
Time Frame: Up to 8 weeks post-treatment
|
The Upper-Extremity Fugl-Meyer scale is a validated clinical scale to evaluate motor function in post-stroke patients.
|
Up to 8 weeks post-treatment
|
Change in Modified Tardieu Scale total upper limb score following 5 days of treatment as compared to baseline
Time Frame: Up to 8 weeks post-treatment
|
The Modified Tardieu Scale is a validated clinical scale to evaluate spasticity in the upper limbs in stroke patients.
|
Up to 8 weeks post-treatment
|
Improvement in subject's self-assessment of their spasticity following 5 days of treatment as compared to baseline
Time Frame: Up to 8 weeks post-treatment
|
An 11-point Numerical Rating Scale will be used for this outcome measure.
|
Up to 8 weeks post-treatment
|
Improvement in spasticity as assessed by an investigator following 5 days of treatment as compared to baseline
Time Frame: Up to 8 weeks post-treatment
|
An 11-point Numerical Rating scale will be used for this outcome measure.
|
Up to 8 weeks post-treatment
|
Change in pain in the spastic limb following 5 days of treatment as compared to baseline
Time Frame: Up to 8 weeks post-treatment
|
A 10-point VAS scale (Wong-Baker Pain Scale) will be used for this outcome measure.
|
Up to 8 weeks post-treatment
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Paget-Blanc A, Chang JL, Saul M, Lin R, Ahmed Z, Volpe BT. Non-invasive treatment of patients with upper extremity spasticity following stroke using paired trans-spinal and peripheral direct current stimulation. Bioelectron Med. 2019 Jul 23;5:11. doi: 10.1186/s42234-019-0028-9. eCollection 2019.
- Estudillo-Guerra MA, Mesia-Toledo I, Rogel N, Yaghoubi N, Ahmed Z, Black-Schaffer R, Morales-Quezada L.Trans-spinal direct current stimulation in spasticity: a literature mini-review. Front. Stroke. 2022 Jul 1;1:921450. doi: 10.3389/fstro.2022.921450.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PMN-003
- 1U44NS104138 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on MyoRegulator® device
-
PathMaker Neurosystems Inc.Spaulding Rehabilitation Hospital; Muscular Dystrophy Association; Sean M. Healey...RecruitingAmyotrophic Lateral SclerosisUnited States
-
Institut National de la Santé Et de la Recherche...PathMaker Neurosystems Inc.CompletedStroke | Muscle SpasticityFrance
-
Northwell HealthTerminatedStroke | Stroke Sequelae | Hemiparesis | Hemiplegia, Spastic | CVA | Spasticity as Sequela of Stroke | Upper Limb HypertoniaUnited States
-
Kepler University HospitalCompletedCholecystolithiasisAustria
-
Medtronic Neurovascular Clinical AffairsCompletedIschemic StrokeUnited States
-
Cefaly TechnologyCompleted
-
Catholic University of the Sacred HeartUnknown
-
Imperial College Healthcare NHS TrustWithdrawnPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Femoral Popliteal OcclusionUnited Kingdom
-
Centre Hospitalier Universitaire de NiceCompleted
-
Alejandro BerensteinRecruitingIntracranial Arteriovenous Malformations | Arterio-venous FistulaUnited States